Riskpilot← Back to searchSign inGet full accessSTIFTELSEN BIOFOKUS
STIActiveOrg 982132924Gaustadalléen 21, 0349 OsloAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 202426 employeeswww.biofokus.no
Revenue 2024
NOK 25,8M
+17% vs 2023
EBITDA margin
4.6%
-9% vs 2023
Equity ratio
65.3%
Financial strength
Net profit 2024
NOK 1,5M
+2% vs 2023
| Revenue | NOK 25,8M | +17% |
| EBITDA | NOK 1,2M | -9% |
| Net profit | NOK 1,5M | +2% |
| Total assets | NOK 33M | +16% |
| Equity | NOK 21,6M | +7% |
| Employees | 26 | — |
Legal name
STIFTELSEN BIOFOKUS
Org number
982132924
Legal form
Stiftelse
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
23. desember 2024
Share capital
NOK 200 000
Employees
26 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Biofokus skal tilrettelegge informasjon om biologisk mangfold for beslutningstakere, samt formidle kunnskap innen fagfeltet bevaringsbiologi.
Address
Gaustadalléen 21, 0349 Oslo
Website
www.biofokus.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 089 | 19 750 | 19 602 | 15 962 | 20 486 | 19 687 | 19 113 | 22 039 | 25 845 |
| Staff expenses | −10 353 | −12 658 | −13 026 | −13 329 | −13 592 | −13 367 | −14 365 | −16 211 | −19 002 |
| EBITDA | 362 | 2 677 | 2 332 | −648 | 2 394 | 1 796 | 760 | 1 306 | 1 194 |
| Depreciation & amort. | −92 | −98 | −89 | −74 | −50 | −46 | −40 | −32 | −30 |
| EBIT | 271 | 2 579 | 2 243 | −722 | 2 344 | 1 750 | 720 | 1 274 | 1 163 |
| Net financials | 152 | 157 | 159 | 208 | 203 | 121 | 236 | 657 | 817 |
| Profit before tax | 423 | 2 736 | 2 402 | −515 | 2 547 | 1 871 | 957 | 1 931 | 1 980 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | 167 | 472 | 498 |
| Net profit | 423 | 2 736 | 2 402 | −515 | 2 547 | 1 871 | 790 | 1 459 | 1 481 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15 099 | 18 520 | 20 498 | 22 023 | 22 493 | 25 413 | 24 870 | 28 374 | 33 024 |
| Equity | 8 799 | 11 535 | 13 937 | 13 422 | 15 969 | 17 840 | 18 630 | 20 089 | 21 570 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 300 | 6 984 | 6 561 | 8 602 | 6 525 | 7 573 | 6 240 | 8 285 | 11 454 |
| Total debt | 6 300 | 6 984 | 6 561 | 8 602 | 6 525 | 7 573 | 6 240 | 8 285 | 11 454 |
EBITDA margin
4.6%
This company
15.8%
Market median
-71% vs market
20162024
Equity ratio
65.3%
This company
38.2%
Market median
+71% vs market
20162024
Return on equity
6.9%
This company
18.4%
Market median
-63% vs market
20162024
Net profit margin
5.7%
This company
8.1%
Market median
-30% vs market
20162024
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20162024
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
20162024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2026 | — | — | |
| Board of Directors | 2023 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of STIFTELSEN BIOFOKUS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Terje Blindheim | Chief Executive Officer | 0 companies |
| Sigve Reiso | Board of Directors | 0 companies |
| Maria Knagenhjelm Hertzberg | Board of Directors | 0 companies |
| Tomas Colin Archer | Board of Directors | 0 companies |
| Gaute Eiterjord | Board of Directors | 0 companies |
| Erik Dahl | Chairman | 0 companies |
| Øivind Gammelmo | Board of Directors | 0 companies |
| Solfrid Helene Lien Langmo | Board of Directors | 0 companies |
| Marie Feiring | Chairman | 0 companies |
| Torbjørn Høitomt | Board of Directors | 0 companies |